Trial Profile
A randomized, double-blind comparison of atomoxetine hydrochloride and placebo for symptoms of attention-deficit/hyperactivity disorder in children and adolescents with autism spectrum disorder.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary)
- Indications Pervasive child development disorders
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 01 Jul 2012 Results published in the Journal of the American Academy of Child and Adolescent Psychiatry.
- 11 Nov 2008 Status changed from active, no longer recruiting to completed, as reported on ClinicalTrials.gov
- 19 Sep 2008 Planned end date changed from 1 May 2010 to 1 Oct 2008, as reported by ClinicalTrials.gov. Actual patient number reported as 98.